Innate Pharma (IPHA) Long-Term Debt Repayments (2019 - 2025)

Innate Pharma (IPHA) has 7 years of Long-Term Debt Repayments data on file, last reported at -$10.4 million in Q4 2025.

• For the quarter ending Q4 2025, Long-Term Debt Repayments fell 8.63% year-over-year to -$10.4 million; the trailing twelve-month figure through Dec 2025 stood at -$22.5 million (down 62.47% YoY), and the FY2025 full-year result was -$10.4 million, down 8.63% from the prior year.
• Long-Term Debt Repayments for Q4 2025 stood at -$10.4 million, down from -$9.5 million in the prior quarter.
• Across five years, Long-Term Debt Repayments topped out at -$1.0 million in Q2 2022 and bottomed at -$10.4 million in Q4 2025.
• The 5-year median for Long-Term Debt Repayments is -$2.2 million (2022), against an average of -$3.9 million.
• The widest annual swing landed in 2022, when Long-Term Debt Repayments advanced 24.68%; it then slumped 275.9% in 2024.
• A 5-year view of Long-Term Debt Repayments shows it stood at -$2.4 million in 2021, then increased by 12.67% to -$2.1 million in 2022, then retreated by 22.9% to -$2.5 million in 2023, then slumped by 275.9% to -$9.5 million in 2024, then declined by 8.63% to -$10.4 million in 2025.
• The last three Long-Term Debt Repayments figures came in at -$10.4 million (Q4 2025), -$9.5 million (Q4 2024), and -$2.5 million (Q4 2023), per Business Quant data.

Peer Comparison